The CSE welcomed FSD Pharma Inc. (CSE:HUGE) to a Market Open at the CSE Media Centre on March 6th, 2020.

FSD Pharma Inc. is a specialty biotech pharmaceutical company that is targeting all legal aspects of the cannabis industry, including cultivation, processing, and manufacturing. As a science-driven company, FSD Pharma’s mission is to leverage their world-leading hydroponic indoor cannabis facility to develop life-saving medicines based on cannabinoid science. It is currently focusing its research and development efforts on novel cannabinoid-based treatments for various ailments, including certain central nervous system disorders, autoimmune skin diseases, and chronic pain. The company is also a licensed producer of medicinal grade cannabis under Canada’s Cannabis Act and Regulation.

“It was indeed a great milestone for FSD Pharma to come back and ring the bell at the CSE,” said CEO Dr. Raza Bokhair, MD. “We have, from what I understand, become your first company that is dual-listed.”

He added, “We have now become one of twelve Canadian domicile companies that are dual-listed in the United States – [the] first CSE company that is dual listed in the United States. And I hope that we will soon be recognized in a league of our own, as the thrust of our business is advancing clinical trials through FDA approved processes.”

Other key executive members of the FSD Pharma team were also in attendance at the Market Open, including Executive Co-Chairman and Founder Anthony Durkacz, and President and Founder Zeeshan Saeed.

View the podcast on this Market Open featuring Dr. Raza Bokhari here.

For more details about the CSE Media Centre, including information on upcoming Market Opens, please visit the CSE website, or follow us on social media.